Results 41 to 50 of about 743,600 (215)

Progressive supranuclear palsy: new concepts

open access: yesArquivos de Neuro-Psiquiatria, 2010
Progressive supranuclear palsy (PSP) is a distinctive form of neurodegenerative disease which affects the brainstem and basal ganglia. Patients present supranuclear ophthalmoplegia, postural instability and mild dementia.
Orlando Graziani Povoas Barsottini   +3 more
doaj   +1 more source

Progressive Supranuclear Gaze Palsy with Predominant Cerebellar Ataxia: A Case Series with Videos [PDF]

open access: yesJournal of Movement Disorders, 2017
Progressive supranuclear palsy (PSP) with predominant cerebellar ataxia (PSP-C) is a rare phenotype of PSP. The clinical and radiological features of this disorder remain poorly characterized.
Zheyu Xu   +3 more
doaj   +1 more source

REM sleep behavior in Parkinson disease: Frequent, particularly with higher age.

open access: yesPLoS ONE, 2020
This retrospective single-center polysomnography-based study was designed to assess the frequency of REM sleep behavior disorder (RBD) in consecutive patients with Parkinsonism, including Parkinson disease, dementia with Lewy bodies, multiple system ...
Heide Baumann-Vogel   +5 more
doaj   +1 more source

Clinical Approach to Progressive Supranuclear Palsy [PDF]

open access: yesJournal of Movement Disorders, 2016
Sixty years ago, Steele, Richardson and Olszewski designated progressive supranuclear palsy (PSP) as a new clinicopathological entity in their seminal paper. Since then, in addition to the classic Richardson’s syndrome (RS), different clinical phenotypic
Helen Ling
doaj   +1 more source

Progressive Supranuclear Palsy with Predominant Cerebellar Ataxia [PDF]

open access: yesJournal of Movement Disorders, 2020
Progressive supranuclear palsy (PSP) is characterized by supranuclear gaze palsy, dystonic rigidity of the neck and upper trunk, frequent falls and mild cognitive impairment.
Shoichiro Ando   +2 more
doaj   +1 more source

Sertraline Treatment Can Mimic Niemann‐Pick Type C Biomarker Profile: A Diagnostic Pitfall

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Oxysterols (cholestane‐3β,5α,6β‐triol and 7‐ketocholesterol) and N‐palmitoyl‐O‐phosphocholineserine (PPCS) are sensitive biomarkers for Niemann‐Pick disease type C (NPC) screening. However, false‐positive results occur, with a biomarker profile suggestive of NPC despite the absence of pathogenic variants in genes involved in NPC or ...
Maria Makrygianni   +19 more
wiley   +1 more source

The Effectiveness of Exercise Programs on Balance, Functional Ability, Quality of Life, and Depression in Progressive Supranuclear Palsy: A Case Study

open access: yesApplied Sciences
Progressive supranuclear palsy is a form of atypical Parkinsonism. People living with Progressive Supranuclear Palsy have various symptoms, such as movement and cognitive disorders, which mainly affect balance and functional ability with an increased ...
Panagiotis Papamichail   +7 more
doaj   +1 more source

DISSOCIATION OF CLINICAL MANIFESTATIONS AND NEUROIMAGING IN PROGRESSIVE SUPRANUCLEAR PALSY (PAIRED CLINICAL CASE OF STEELE-RICHARDSON-OLSHEVSKY SYNDROME)

open access: yesБайкальский медицинский журнал
Relevance. The differential diagnosis of motor neuron diseases is very difficult in practical medical practice. Early diagnosis of this group of diseases, in particular, progressive supranuclear palsy, is of particular importance.
Yury N. Bykov   +4 more
doaj   +1 more source

Apraxia in progressive nonfluent aphasia [PDF]

open access: yes, 2010
The clinical and neuroanatomical correlates of specific apraxias in neurodegenerative disease are not well understood. Here we addressed this issue in progressive nonfluent aphasia (PNFA), a canonical subtype of frontotemporal lobar degeneration that has
Rohrer, J.D., Rossor, M.N., Warren, J.D.
core  

Stage‐Dependent β‐Synuclein Links MRI and Cognitive Decline in Alzheimer's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Synaptic degeneration drives cognitive decline in Alzheimer's disease (AD), but synaptic biomarkers are scarce. Brain‐enriched β‐synuclein emerged as a synaptic damage marker. We investigated its diagnostic, prognostic, and structural correlates across the AD continuum.
Ulaş Ay   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy